Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives

References

• Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018;14(10):857–872. doi:10.1080/1744666X.2018.152172230204521
   PubMed Web of Science ®Google Scholar
• Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2016;1:690–697. doi:10.1182/asheducation-2016.1.690
   Web of Science ®Google Scholar
• Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A; British Society for Haematology. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395–411. doi:10.1111/bjh.1447828005293
   PubMed Web of Science ®Google Scholar
• Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A; British Society for Haematology Guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208–220. doi:10.1111/bjh.1465428369704
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320–330. doi:10.1111/bjh.1510929363757
   PubMed Web of Science ®Google Scholar
• Wang M, Wang W, Abeywardane A, et al. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King’s College Hospital. Biol Blood Marrow Transplant. 2015;21(1):60–66. doi:10.1016/j.bbmt.2014.09.00925262883
   PubMed Web of Science ®Google Scholar
• González-Vicent M, Sanz J, Fuster JL, et al. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): a retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). Transfus Med Rev. 2018;32:179–185.
   Web of Science ®Google Scholar
• Kruizinga MD, van Tol MJD, Bekker V, et al. Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2018;24(4):772–778. doi:10.1016/j.bbmt.2017.12.78229277513
   PubMed Web of Science ®Google Scholar
• Holbro A, Abinun M, Daikeler T. Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol. 2012;157(3):281–290. doi:10.1111/j.1365-2141.2012.09070.x22360687
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925–2928. doi:10.1182/blood-2003-10-359715070665
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116:3180–3184. doi:10.1182/blood-2010-06-28864720634373
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biological studies. Blood. 2012;119:3691–3697. doi:10.1182/blood-2011-10-38851222267606
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393–399. doi:10.1111/bjh.1254123981017
   PubMed Web of Science ®Google Scholar
• Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92:23–27. doi:10.1002/ajh.2457027696475
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124:2930–2936. doi:10.1182/blood-2014-06-58302125232059
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from 8 Italian Reference Centers. Am J Hematol. 2018;93(9):E243–E246. doi:10.1002/ajh.2521229981267
   PubMed Web of Science ®Google Scholar
• Sanz J, Arriaga F, Montesinos P, et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant. 2007;39(9):555–561. doi:10.1038/sj.bmt.170564117351645
   PubMed Web of Science ®Google Scholar
• Chang TY, Jaing TH, Wen YC, Huang IA, Chen SH, Tsay PK. Risk factor analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in children. Medicine (Baltimore). 2016;95(46):e5396. doi:10.1097/MD.000000000000486427861376
   PubMed Web of Science ®Google Scholar
• Neely JA, Dvorak CC, Pantell MS, Melton A, Huang JN, Shimano KA. Autoimmune cytopenias in pediatric hematopoietic cell transplant patients. Front Pediatr. 2019;7:171. doi:10.3389/fped.2019.0017131131266
   PubMed Web of Science ®Google Scholar
• Hosoba S, Jaye DL, Cohen C, Roback JD, Waller EK. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2015;55(2):259–264. doi:10.1111/trf.1281525156334
   PubMed Web of Science ®Google Scholar
• Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284. doi:10.1002/jca.2127623868759
   PubMed Web of Science ®Google Scholar
• Szczepiorkowski ZM, Winters JL, Bandarenko N, et al.; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83–177. doi:10.1002/jca.20240.20568098
   PubMed Web of Science ®Google Scholar
• Sanz J, Arango M, Carpio N, et al. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. Bone Marrow Transplant. 2014;49(8):1084–1088. doi:10.1038/bmt.2014.10724887383
   PubMed Web of Science ®Google Scholar
• Bhatt V, Shune L, Lauer E, et al. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab. Bone Marrow Transplant. 2016;51(12):1579–1583. doi:10.1038/bmt.2016.22827643868
   PubMed Web of Science ®Google Scholar
• Faraci M, Zecca M, Pillon M, et al.; Italian Association of Paediatric Haematology and Oncology. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant. 2014;20(2):272–278. doi:10.1016/j.bbmt.2013.11.014.24274983
   PubMed Web of Science ®Google Scholar
• Minakawa K, Ohto H, Yasuda H, et al. Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant. Transfusion. 2018;58(7):1606–1610. doi:10.1111/trf.1463429664112
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783–4785. doi:10.1182/blood-2010-06-29183120841509
   PubMed Web of Science ®Google Scholar
• Chao MM, Levine JE, Ferrara JL, et al. Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H. Pediatr Blood Cancer. 2008;50(4):917–919. doi:10.1002/pbc.2118717417790
   PubMed Web of Science ®Google Scholar
• Park JA, Lee HH, Kwon HS, Baik CR, Song SA, Lee JN. Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia. Transfus Med Rev. 2016;30(1):6–14. doi:10.1016/j.tmrv.2015.09.00126481836
   PubMed Web of Science ®Google Scholar
• Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115(4):915. doi:10.1182/blood-2009-12-25599220110437
   PubMed Web of Science ®Google Scholar
• Danchaivijitr P, Yared J, Rapoport AP. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011;86(3):331–332. doi:10.1002/ajh.21950
   PubMed Web of Science ®Google Scholar
• Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132(5):547–550. doi:10.1182/blood-2018-03-83541329898955
   PubMed Web of Science ®Google Scholar
• Poon LM, Koh LP. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant. 2012;47(6):870–871. doi:10.1038/bmt.2011.17621874058
   PubMed Web of Science ®Google Scholar
• Rovira J, Cid J, Gutiérrez-García G, et al. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev. 2013;27(3):166–170. doi:10.1016/j.tmrv.2013.02.00423562007
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Davies SM, Grimley MS, et al. Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014;20(10):1654–1659. doi:10.1016/j.bbmt.2014.06.03224979732
   PubMed Web of Science ®Google Scholar
• Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2(19):2550–2553. doi:10.1182/bloodadvances.201802088330291113
   PubMed Web of Science ®Google Scholar
• Koreth J, Kim HT, Lange PB, et al. A bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a Phase II trial. Biol Blood Marrow Transplant. 2015;21(11):1907–1913. doi:10.1016/j.bbmt.2015.05.02726055298
   PubMed Web of Science ®Google Scholar
• Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans Syndrome (ES): a single institution’s experience. J Pediatr Hematol Oncol. 2017;39(6):420–424. doi:10.1097/MPH.000000000000081828267088
   PubMed Web of Science ®Google Scholar
• Miano M, Calvillo M, Palmisani E, et al. Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol. 2014;167(4):571–574. doi:10.1111/bjh.1301024975111
   PubMed Web of Science ®Google Scholar
• Valentini RP, Imam A, Warrier I, et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant. 2006;10(3):358–361. doi:10.1111/j.1399-3046.2005.00460.x16677361
   PubMed Web of Science ®Google Scholar
• Acquazzino MA, Fischer RT, Langnas A, Coulter DW. Refractory autoimmune haemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor. Pediatr Transplant. 2013;17(5):466–471. doi:10.1111/petr.1210123730873
   PubMed Web of Science ®Google Scholar
• Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101–106. doi:10.1111/j.1365-2141.2009.07595.x19208097
   PubMed Web of Science ®Google Scholar
• Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2(19):2543–2549. doi:10.1182/bloodadvances.201802419030291112
   PubMed Web of Science ®Google Scholar
• Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010;115(11):2283–2291. doi:10.1182/blood-2009-12-25599220068220
   PubMed Web of Science ®Google Scholar
• Jäger U, D’Sa S, Schörgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2019;133(9):893–901. doi:10.1182/blood-2018-06-85693030559259
   PubMed Web of Science ®Google Scholar
• Clinical Trial Bioverativ Therapeutics Inc. A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study). Available from: https://clinicaltrials.gov/ct2/show/NCT03347422. NLM identifier: NCT03347422. Accessed November 20, 2017.
   Google Scholar
• Clinical Trial Bioverativ Therapeutics Inc. A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study). Available from: https://clinicaltrials.gov/ct2/show/NCT03347396. NLM identifier: NCT03347396. Accessed November 20, 2017.
   Google Scholar
• Clinical trial Apellis Pharmaceuticals, Inc.Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD. Available from: https://clinicaltrials.gov/ct2/show/NCT03226678. NLM identifier: NCT03226678. Accessed July 24, 2017.
   Google Scholar
• Tolbert VP, Goldsby R, Huang J, et al. Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report. Blood. 2016;128:4819. doi:10.1182/blood-2016-06-724161
   Google Scholar
• Hess J, Su L, Nizzi F, et al. Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept. Transfusion. 2018;58(9):2122–2127. doi:10.1111/trf.1490730179262
   PubMed Web of Science ®Google Scholar
• Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcon GS. Abatacept for the treatment of systemic lupus rythematosus. Expert Opin Investig Drugs. 2016;25(4):493–499. doi:10.1517/13543784.2016.1154943
   PubMed Web of Science ®Google Scholar
• Lee S, Moon JS, Lee CR, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016;137(1):327–330. doi:10.1016/j.jaci.2015.08.03626478010
   PubMed Web of Science ®Google Scholar
• Koura DT, Horan JT, Langston AA, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013;19(11):1638–1649. doi:10.1016/j.bbmt.2013.09.00324047754
   PubMed Web of Science ®Google Scholar